12th Congress of the European Hematology ... - Haematologica

with development of BC/AP. 2. EVI-1 expression in K562: expression was
analyzed in this cell line after treatment with commonly used drugs for
CML (BU, HU, Ara-C, IFN, Imatinib). A decrease in the gene expression
was only observed after treatment with Imatinib, while its levels
remained unchanged after the use of the other drugs, even though they
have an antiproliferative effect on K562.
Figure 1.
Conclusions. a) A high percentage of CML show an increase in EVI-1
expression at diagnosis and during BC, disappearing after treatment with
Imatinib. b) EVI-1 expression decreases alongside BCR-ABL expression.
Loss of response to Imatinib is associated to recovery of EVI-1 expression.
c) A repression of EVI-1 is detected on K562 treated with Imatinib.
This is not found when treated with the other above mentioned drugs,
suggesting that EVI-1 expression depends on the activity of BCR-ABL.
d) EVI-1 expression could be a marker of the antileukemic effect of anti
TK drugs such as Imatinib.
1442
CUTANEOUS LESIONS ASSOCIATED WITH HIGH RISK PRIMARY MYELODYSPLASIA
M. Dalamaga, 1 G. Sotiropoulos, 2 A. Matekovits, 3 A. Lekka, 2
E. Papadavid4 1 NIMTS General Hospital, ATHENS; 2 Laboratory of Hematology, NIMTS
General, ATHENS; 3 Department of Internal Medicine, NIMTS G, ATHENS;
4 Department of Dermatology, University of, ATHENS, Greece
Background/Aim. Most previews studies assessed the autoimmune
inflammatory rheumatic disorders in patients with myelodysplastic syndrome
(MDS). There is no study of skin manifestations in a cohort of
MDS patients nor that correlated the cutaneous findings with immunologic
parameters and prognostic features of MDS. The aim of the present
study was to assess the cutaneous findings in a cohort of 84 MDS
patients in relation to immunologic parameters or prognostic features of
MDS in order to clarify their potential clinical significance. Methods. We
studied a cohort of 84 newly diagnosed MDS patients in order to assess
the cutaneous findings present at the time of diagnosis or during 1 to 3
years of follow-up. We described the clinical variety of cutaneous findings
ascertained by histology. We also looked for any association
between the group of MDS patients with skin manifestations and MDS
subtype, immunologic and prognostic features highlighting transformation
to acute leukaemia (high and low risk patients). The laboratory
exams performed at the time MDS was diagnosed were marrow and
trephine biopsy, peripheral blood count, erythrocyte sedimentation rate
(ESR), serum protein electrophoresis (SPE), determination of anti-nuclear
antibodies (ANA), rheumatoid factor (RF) and direct Coombs test. The
blood specimens used in this study were collected prior to the initiation
of any therapeutic approach such as chemotherapy and/or blood transfusion.
Statistical analysis of the data was performed using SPSS version
10 statistical software package. Results. 21 MDS patients presented cutaneous
manifestations: 1 patient developed leukemia cutis, 6 patients
photosensitivity not associated with autoimmune disease, 3 prurigo
nodularis, 2 Sweet’s syndrome, 6 leukocytoclasitc vasculitis, 2 ecchymoses
and purpura associated with preexisting relapsing polychondritis,
1 patient subcutaneous nodules associated with Wegener’s granulomatosis
(an exceptional finding) and 1 patient with malar rash and oral
ulcers associated with preexisting SLE. Adjusted for age and gender, the
presence of skin findings constitutes a significant predictor of the high
risk MDS subgroup (OR: 3.59, 95% C.I: 1.18-10.92). Hypergammaglob-
ulinemia was significant higher in the MDS subgroup with skin findings
(p=0.03). Conclusion. In conclusion, most MDS patients with cutaneous
manifestations belong to the high risk MDS subgroup. This investigation
highlights the need to search meticulously for cutaneous manifestations
by performing early skin biopsies in hematologic patients, as the skin
could reveal prodromal signs of an underlying bone marrow disorder in
transformation.
1443
LUPUS ANTICOAGULANT (LA) IN INFECTIOUS DISEASE . A REPORT OF THREE CASES
N. Fernandez Mosteirin, C. Salvador Osuna, A. Godoy, N. Padron,
B. Soria, F. Sevil, M. Torres, J.F. Lucia, M. Giralt
Hospital Universitario Miguel Servet, ZARAGOZA, Spain
Background. Transient and non related with bledding and/or thrombosis
LA tend to appear after infections, and generally is not associated
with any underlying disorder. This fact has been reported in children
with viral infections in most cases in literature. The finding of LA is usually
detected during routine laboratory investigation of a prolonged
aPTT. Aim. We describe 3 patients with AL following infectious disease
studied in our center for a period of five months. Patients. In all patients
LA was detected after evaluation of prolonged aPTT in the course of
infectious disease. Clinical and laboratory findings are reported in Table
1. Biologic assay of factors II, V, VII, VIII, IX, X, XI, XII and von Willebrand
factor were at normal levels in patients 1 and 3. Patient 2 who had
a prolonged PT presented a mild hypoprothrombinemia (FII 42.2%)
without hematological symptoms. Patient 3 presented mild postraumatic
subcutaneous bleeding that improved spontaneously within a week.
Patient 1 and 2 were asymptomatic. Infectious disease improved in all
patients.
Table 1.
12 th Congress of the European Hematology Association
Case1 case 2 Case 3
Gender/Age (y) Female/74 Female/84 Male/2
PT (8.5-1.3’’) 12.30 32.2 13.0
aPTT (26-39’’) 71.6 79.7 66.0
Mixing test 50.7 43 55.2
dRVVT ratio (